![logo](/logos/ENTX.webp)
Entera Bio Ltd.
NASDAQ:ENTX
1.79 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Entera Bio Ltd. |
Symbool | ENTX |
Munteenheid | USD |
Prijs | 1.79 |
Beurswaarde | 65,021,034 |
Dividendpercentage | 0% |
52-weken bereik | 0.52 - 3.35 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Ms. Miranda J. Toledano M.B.A. |
Website | https://www.enterabio.com |
An error occurred while fetching data.
Over Entera Bio Ltd.
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)